Physician profile
Caylor Johnson
NPI 1336717610
$4,250.89
in general payments reported to CMS, 2019-2025
37 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.48 · 2022: $642 · 2023: $724 · 2024: $1,151 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,502 · Education: $36.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,501.55 |
| Education | $36.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.65 | 2022-2025 | |
| Janssen Biotech, INC. | $544.28 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $310.90 | 2023-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $267.95 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.87 | 2022-2025 | Xifaxan, Cycloset |
| Phathom Pharmaceuticals, INC. | $172.22 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $163.93 | 2025 | Ibsrela |
| Corium, LLC | $160.71 | 2022-2023 | Azstarys |
| Lilly USA, LLC | $143.91 | 2022-2025 | Omvoh, Mounjaro |
| Idorsia Pharmaceuticals US INC | $116.63 | 2022-2023 | Quviviq |
| Pfizer INC. | $104.13 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $90.42 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $88.97 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $86.46 | 2023-2024 | Sucraid, Sucraid |
| Biohaven Pharmaceutical Holding Company Ltd. | $79.01 | 2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caylor Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.